Oxford Biomedica starts search for new CEO as Dawson steps down
Oxford Biomedica starts search for new CEO as Dawson steps down
Read moreThu, 15th Apr 2021 09:02
Oxford Biomedica starts search for new CEO as Dawson steps down
Read more(Sharecast News) - Oxford Biomedica chief executive John Dawson said he was stepping down after 13 years at the helm of the Gene and cell therapy firm which helped develop a Covid-19 vaccine with AstraZeneca.
Read moreOxford Biomedica wins new agreement for LentiVector platform
Read more(Sharecast News) - Gene and cell therapy group Oxford Biomedica on Wednesday said it had signed a new license and supply agreement on its LentiVector platform with US-based Cabaletta Bio.
Read moreLONDON BROKER RATINGS: BofA starts Pod Point at Buy; Barclays cuts DCC
Read moreOxford Biomedica in license and supply deals with Novartis and Arcellx
Read more(Sharecast News) - Gene and cell therapy group Oxford Biomedica has struck new license and supply agreements for its lentiviral vectors.
Read moreOxford BioMedica licences technology for cystic fibrosis treatment
Read more(Sharecast News) - Gene and cell therapy firm Oxford Biomedica said on Tuesday that pharmaceutical giant Boehringer Ingelheim had exercised its option to license its lentiviral vector technology to manufacture, register and commercialise a treatment for cystic fibrosis.
Read moreLONDON BROKER RATINGS: Keppler Cheuvreux raises Pearson to Hold
Read moreLONDON BROKER RATINGS: Investec prefers 888 over Entain
Read moreLONDON MARKET CLOSE: Stocks up as Evergrande fears soothed before Fed
Read moreTOP NEWS: Oxford BioMedica sales double; Serum Institute buys stake
Read more(Sharecast News) - Covid-19 vaccine producer Oxford Biomedica swung to a profit in the half year on the back of a surge in revenues through its partnership deal with AstraZeneca and announced that Serum Institute of India has agreed to invest £50m in the group in return for a 3.9% stake in the company.
Read more(Sharecast News) - Covid-19 vaccine producer Oxford Biomedica swung to a profit in the half year on the back of a surge in revenues through its partnership deal with AstraZeneca and announced that Serum Institute of India has agreed to invest £50m in the group in return for a 3.9% stake in the company.
Read more